Jamaica Plain, MA, United States of America

John Monteith Lincecum

This inventor holds 10 USPTO granted patents and 2 published patent applications, plus 1 CIPO patent and 4 EPO patents. Top assignees: Als Therapy Development Institute, Biogen Ma Inc.. Active years: 2013-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: John Monteith Lincecum. Retrieved from https://idiyas.com/inventor/john-monteith-lincecum

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 10 (Patent Applications = 2)

% Patents Active = 90.0

CIPO Patents = 1

EPO Patents = 4 (Patent Applications = 2)

Average Co-Inventor Count = 4.9

ph-index = 4

Forward Citations = 28(Granted Patents)

Company Filing History:

9 out of 19

Als Therapy Development Institute

Years Active: 2013-2025

Loading Chart...

10 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12275793 - Anti-CD40L antibodies and methods for treating CD40L-related diseases or disorders (2025-04-14),

2. 11692040 - Anti-CD40L antibodies and methods for treating CD40L-related diseases or disorders (2023-07-04),

3. 11014990 - Anti-CD40L antibodies (2021-05-25),

4. 10683356 - Methods of treating a CD40L associated disease or disorder by administering anti-CD40L antibodies (2020-06-16),

5. 10106618 - Anti-CD40L antibodies (2018-10-23),

6. 9775899 - Treating neurological disorders (2017-10-03),

7. 9044459 - Method for the treatment of neurodegenerative diseases (2015-06-02),

8. 8946301 - Targeting of T-lymphocytes to treat amyotrophic lateral sclerosis (2015-02-03),

9. 8673308 - Targeting of CD8+ T-lymphocytes to treat neurodegenerative diseases (2014-03-18),

10. 8435514 - Method for the treatment of neurodegenerative diseases (2013-05-07),

Title: John Monteith Lincecum: Innovator in CD40L-Related Treatments

Introduction

John Monteith Lincecum is a notable inventor based in Jamaica Plain, MA (US). He has made significant contributions to the field of medicine, particularly in the development of treatments related to CD40L-associated diseases. With a total of 10 patents to his name, Lincecum's work has the potential to impact many lives.

Latest Patents

Lincecum's latest patents include innovative anti-CD40L antibodies and methods for treating CD40L-related diseases or disorders. These anti-human CD40L antibodies are engineered to lack the ability to activate platelets, providing a new avenue for treating patients suffering from CD40L-associated diseases. His work in this area demonstrates a commitment to advancing medical science and improving patient outcomes.

Career Highlights

Throughout his career, Lincecum has worked with prominent organizations such as ALS Therapy Development Institute and Biogen MA Inc. His experience in these companies has allowed him to collaborate with leading experts in the field and contribute to groundbreaking research.

Collaborations

Lincecum has collaborated with notable individuals in his field, including Steven N. Perrin and Alan Gill. These partnerships have further enhanced his research and development efforts, leading to significant advancements in the treatment of CD40L-related conditions.

Conclusion

John Monteith Lincecum is a distinguished inventor whose work in the field of CD40L-related treatments showcases his dedication to medical innovation. His contributions through patents and collaborations highlight the importance of research in improving healthcare solutions.

Profile summary based on public USPTO records.